Eye stroke treatment put to the test: can clot busters save sight?
NCT ID NCT04965038
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether giving a clot-busting drug (tenecteplase or alteplase) within 4.5 hours of an eye stroke could restore vision. Eye stroke, or central retinal artery occlusion, is a blockage in the eye's main artery that often causes permanent vision loss. The trial aimed to enroll 127 people but was terminated early, so its findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Tenecteplase or Alteplase (clot-busting drugs given intravenously)
- What this could lead to
- If effective, this could provide a proven emergency treatment for eye stroke, potentially restoring vision in many patients.
- What could go wrong
- The trial was terminated early, so results are limited. The treatment carries a risk of bleeding, and its benefit remains unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
127 people
The number who actually took part.
- Started
-
Oct 2022
- Finished
-
Apr 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Acute non-arteritic CRAO (i.e. sudden, painless monocular vision loss) ≤ 12 hours after symptom onset confirmed by an experienced ophthalmologist through assessment of: BCVA, intraocular pressure, swinging flash light test (relative afferent pupil defect), slit-lamp biomicroscopy, fundoscopy, and OCT of the macula of both eyes\* (\*within the 4.5-hour time window: to be skipped if not feasible ≤ 10 minutes; beyond the 4.5-hour time window: mandatory) * BCVA of LogMAR ≥ 1.3 in the affected eye (functional blindness according to WHO ICD-11) * Reading must have been possible with the affected eye before CRAO (LogMAR ≤ 0.5) * Neurological examination performed by an experienced stroke neurologist * Brain imaging as per local standard for acute retinal ischemia/stroke assessment, either cranial computed tomography (CT) or cranial magnetic resonance imaging (MRI) Exclusion Criteria: * Suspected giant cell arteritis * Other-than-CRAO cause of acute visual loss (e.g., retinal detachment, vitreous hemorrhage, acute glaucoma, acute optic neuritis) * BCVA of LogMAR \< 1.3 or rapidly improving vision in the affected eye * Acute ischemic stroke with indication for on-label intravenous thrombolysis (IVT) * Any co-existing or terminal disease with anticipated life expectancy of \< 3 months * Prior participation in the REVISION trial
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Central retinal artery occlusion are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Tuebingen
Tübingen, 72076, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.